Wednesday, April 24, 2024 7:11:23 AM
Recent CVKD News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2024 08:05:31 PM
- Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference • PR Newswire (US) • 09/23/2024 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/05/2024 08:59:33 PM
- Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients • PR Newswire (US) • 08/22/2024 01:00:00 PM
- Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients • PR Newswire (US) • 08/20/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/20/2024 10:03:04 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 10:03:22 AM
- Cadrenal Therapeutics to Present at Upcoming Investor Conferences • PR Newswire (US) • 08/14/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:05:45 PM
- Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update • PR Newswire (US) • 08/07/2024 08:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 08:02:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 01:10:15 PM
- Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs • PR Newswire (US) • 08/06/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 08:05:22 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/12/2024 08:10:10 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 06/11/2024 09:27:28 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/11/2024 09:25:39 PM
- Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients • PR Newswire (US) • 06/03/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/29/2024 09:27:54 PM
- Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 • PR Newswire (US) • 05/23/2024 01:00:00 PM
- Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update • PR Newswire (US) • 05/09/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 10:23:10 AM
- Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024 • PR Newswire (US) • 04/11/2024 08:30:00 PM
- Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts • PR Newswire (US) • 04/09/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 01:15:09 PM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM
Unitronix Corp Unveils Cryptocurrency Investment Portfolio Strategy • UTRX • Oct 2, 2024 8:40 AM
Integrated Ventures, Inc Reports Total 2024 Revenues Of $5,863,935 vs $3,862,849 for 2023. • INTV • Oct 1, 2024 9:00 AM
Nightfood Signs Letter of Intent to Acquire Los Angeles Cooking School, Integrating Automation and Robotics with World-Class Culinary Training • NGTF • Oct 1, 2024 8:30 AM
ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • COOP • Oct 1, 2024 7:00 AM
Element79 Gold Corp secures loi for launching tailings reprocessing business in Arequipa, Peru • ELMGF • Oct 1, 2024 6:38 AM